Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further found that morphine increased colony formation and replating capacity of CD34 stem/progenitor derived from BP-CML patients.
|
31615652 |
2019 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
It induces apoptosis CD34 stem/progenitor cells isolated from patients with blast phase CML.
|
30301525 |
2018 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further demonstrate that ropivacaine induces apoptosis and inhibits colony formation in CD34 progenitor or stem cells derived from patients with blast phase-CML.
|
29549929 |
2018 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
BLT2 inhibition induces apoptosis, inhibits proliferation, colony formation and self-renewal capacity of CD34(+) cells from TKI-resistant BP-CML patients.
|
26966074 |
2016 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our investigations revealed an increased localization of p27(kip1) in the cytoplasm of CD34(+) cells in the blast phase compared to chronic phase.
|
24098519 |
2013 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore isolated subsets of CD34(+) stem/progenitor cells from normal donors and from patients with chronic phase or blast crisis CML.
|
21132730 |
2011 |
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular or pharmacologic interference with SK-1/S1P2 restored PP2A-dependent Bcr-Abl1 dephosphorylation, and enhanced imatinib- or nilotinib-induced growth inhibition in primary CD34(+) mononuclear cells obtained from chronic phase and blast crisis CML patients, K562/IMA-3 or LAMA4/IMA cells, and 32Dcl3 murine progenitor cells, expressing the wild-type or mutant (Y253H or T315I) Bcr-Abl1 in situ.
|
21527515 |
2011 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
|
19723894 |
2009 |
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, strong antiproliferative effects of PHA-739358 were observed in CD34(+) cells derived from untreated CML patients and from IM-resistant individuals in chronic phase or blast crisis, including those harboring the T315I mutation.
|
18268096 |
2008 |
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Upon C/EBPalpha activation, expression of c-Myb and GATA-2 was repressed in 32D-BCR/ABL, K562, and chronic myelogenous leukemia (CML) blast crisis (BC) primary cells but only c-Myb levels decreased slightly in CD34(+) normal progenitors.
|
18550858 |
2008 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, altered expression/function of RBPs leads to increased resistance to apoptotic stimuli, enhanced survival, growth advantage, and differentiation arrest of CD34+ progenitors from patients in CML blast crisis.
|
17925491 |
2008 |
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data are in accordance with a BCR-ABL-c-MYC-miR-17-92 pathway that mediates enhanced miRNA expression in CP but not BC CML CD34(+) cells.
|
17284533 |
2007 |
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
|
16442619 |
2006 |
Blast Phase
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In vitro STI-571 treatment of CD34(+) cells from patients in blast crisis markedly increased the CXCR4 transcript and CXCR4 membrane expression.
|
15805265 |
2005 |
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigate here whether a feature of disease progression (i.e., elevated expression of Bcr-Abl in CD34+ progenitor cells from CML patients in blast crisis) has any bearing on the kinetics of resistance to imatinib.
|
16204063 |
2005 |
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All CP and BC samples displayed centrosome alterations as compared with corresponding CD 34+control cells.
|
15858613 |
2005 |
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of leukemic blasts from patients with acute lymphoblastic leukemia, acute myeloid leukemia, and chronic myeloid leukemia in blast crisis revealed that CDCP1 is predominantly expressed on CD34(+)CD133+ myeloid leukemic blasts.
|
15153610 |
2004 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significantly, treatment with SAHA also down-regulated Bcr-Abl levels and induced apoptosis of CD34(+) leukemia blast progenitor cells derived from patients who had developed progressive blast crisis (BC) of chronic myelocytic leukemia (CML) while receiving therapy with imatinib.
|
12446442 |
2003 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was similar in leukocytes and CD34(+) cells from healthy persons (n = 44) and patients with CML in chronic phase (CP; n = 60) but significantly increased in patients with CML in blast crisis (BC; n = 20) (P <.0001).
|
11861294 |
2002 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
The down-regulation of DNA-PKcs was reversible in CD34(+) CML cells suggesting that this approach might offer a novel and powerful therapeutic strategy in this disease, especially to delay the blast crisis.(Blood.2001;97:2084-2090)
|
11264175 |
2001 |
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FAS/APO-1 antigen was expressed by the cells of 34% of the pts in CML blast crisis (BC) and directly correlated with the the expression of CD34, CD13 and CD14 differentiation antigens.
|
10500825 |
1999 |
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the leukemic cells occurring during blast crisis of one of our patients displayed the typical features of a stem cell leukemia (CD34+, CD19-, CD2-, myeloperoxidase-).
|
7795240 |
1995 |